{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:14:27Z","timestamp":1758046467979,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.pharma.2012.03.001","type":"journal-article","created":{"date-parts":[[2012,4,9]],"date-time":"2012-04-09T20:42:42Z","timestamp":1334004162000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Atteintes articulaires atypiques au cours d\u2019une maladie de Still de l\u2019adulte r\u00e9fractaire\u00a0: efficacit\u00e9 des antagonistes de l\u2019interleukine-6 (tocilizumab)"],"prefix":"10.1016","volume":"70","author":[{"given":"A.","family":"Rkiouak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ennibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zinebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Akhouad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Reggad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rabhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Chaari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2012.03.001_bib0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still's disease","volume":"63","author":"Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.pharma.2012.03.001_bib0010","series-title":"Maladies et syndromes syst\u00e9miques, 1\u00a0vol., 4e \u00e9dition","first-page":"449","article-title":"Maladie de Still de l\u2019adulte","author":"Pouchot","year":"2000"},{"key":"10.1016\/j.pharma.2012.03.001_bib0015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","article-title":"Proposal for a new set of classification criteria for adult-onset Still disease","volume":"81","author":"Fautrel","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.pharma.2012.03.001_bib0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1\u00a0receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease. Preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharma.2012.03.001_bib0025","first-page":"653","article-title":"Interleukin 6: a possible marker of disease activity in adult onset Still's disease","volume":"14","author":"Scheinberg","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.pharma.2012.03.001_bib0030","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharma.2012.03.001_bib0035","series-title":"Immunologie","first-page":"116","article-title":"Propri\u00e9t\u00e9s principales des diverses cytokines","author":"Chatenoud","year":"1999"},{"key":"10.1016\/j.pharma.2012.03.001_bib0040","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2741\/1341","article-title":"Cytokines and fever","volume":"9","author":"Conti","year":"2004","journal-title":"Front Biosci"},{"issue":"2","key":"10.1016\/j.pharma.2012.03.001_bib0045","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1053\/jhep.2003.50318","article-title":"Massive liver growth inmice induced by systemic interleukin 6\u00a0administration","volume":"38","author":"Zimmers","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.pharma.2012.03.001_bib0050","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1182\/blood.V87.6.2525.bloodjournal8762525","article-title":"Ferritin translation by interleukin-1\u00a0and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes","volume":"87","author":"Rogers","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2012.03.001_bib0055","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease","volume":"40","author":"Fujii","year":"2001","journal-title":"Rheumatol"},{"key":"10.1016\/j.pharma.2012.03.001_bib0060","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult onset Still's disease","volume":"3","author":"Choi","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.pharma.2012.03.001_bib0065","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0248-8663(05)80133-X","article-title":"Arthropathies digitales, une complication exceptionnelle de la maladie de Still","volume":"14","author":"Hachulla","year":"1993","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.pharma.2012.03.001_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10067-007-0648-4","article-title":"Adult onset Still's disease: a study of 14\u00a0cases","volume":"27","author":"Singh","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.pharma.2012.03.001_bib0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.49.5.283","article-title":"Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed-up for more than 10\u00a0years","volume":"49","author":"Cabane","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharma.2012.03.001_bib0080","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.revmed.2006.05.003","article-title":"Profils \u00e9volutifs et marqueurs pronostiques de la maladie de Still de l\u2019adulte. Analyse d\u2019une s\u00e9rie monocentrique de 17\u00a0patients","volume":"27","author":"Fraisse","year":"2006","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.pharma.2012.03.001_bib0085","first-page":"262","article-title":"and the CRI","volume":"64","author":"Fautrel","year":"2005","journal-title":"Tumor necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20\u00a0cases. Ann Rheum Dis"},{"key":"10.1016\/j.pharma.2012.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still's disease","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharma.2012.03.001_bib0095","first-page":"733","article-title":"Adalimumab (anti- TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report","volume":"23","author":"Benucci","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.pharma.2012.03.001_bib0100","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still's disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharma.2012.03.001_bib0105","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","article-title":"Refractory adult onset Still's disease successfully treated with anakinra","volume":"64","author":"Vasques","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharma.2012.03.001_bib0110","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.lpm.2011.03.012","article-title":"Les antagonistes de l\u2019interleukine-6 (tocilizumab) dans la maladie de Still r\u00e9fractaire de l\u2019adulte","volume":"40","author":"Sekkach","year":"2011","journal-title":"Presse Med."},{"key":"10.1016\/j.pharma.2012.03.001_bib0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2008.088179","article-title":"Tocilizumab for multirefractory adult-onset Still's disease","volume":"68","author":"De Bandt","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharma.2012.03.001_bib0120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/BOR.0b013e3283295fec","article-title":"Clinical value of blocking IL-6\u00a0receptor","volume":"21","author":"Mima","year":"2009","journal-title":"Curr Opin Rheumatol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450912000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:30:04Z","timestamp":1757719804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450912000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0003450912000314"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2012.03.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atteintes articulaires atypiques au cours d\u2019une maladie de Still de l\u2019adulte r\u00e9fractaire\u00a0: efficacit\u00e9 des antagonistes de l\u2019interleukine-6 (tocilizumab)","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2012.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}